QUICK ANSWER · AEO / GEO
An endogenous redox cofactor, not a peptide; evidence depends strongly on precursor, formulation and route.
ENTITY FACTS
What should readers identify first?
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
FAQ · ANSWER ENGINE
Frequently asked questions
What is NAD+?
NAD+ is described pharmacologically as Endogenous redox cofactor and metabolic co-substrate; not a peptide. An endogenous redox cofactor, not a peptide; evidence depends strongly on precursor, formulation and route.
Does NAD+ have strong evidence?
PrimeCoreBio records Evidence Grade C. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is NAD+ approved everywhere?
No global conclusion should be inferred. PrimeCore Class C must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.